Cancer / Immunology
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, o...
July 16, 2026 | News
First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sy...
July 16, 2026 | News
Japanese patent granted for technology that inhibits TCTP released from dead tumor cells using antibodies to suppress the accumulatio...
July 15, 2026 | News
Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, announced that the first participant has bee...
July 15, 2026 | News
Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Dru...
July 14, 2026 | News
Taiwan-listed biotech looks to expand the value of its lead oncology asset through combination research with late-stage cancer drug resistance specialist I...
July 13, 2026 | News
Pharma Co., Ltd., a clinical-stage biotechnology company focused on novel therapies targeting amino acid transporters, and Uniphar, a leading international...
July 08, 2026 | News
Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests Arima Genomics, Inc., a cancer diagnostics com...
July 07, 2026 | News
Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, announced that it has entered into a strategic collaboration agreement with AstraZeneca (...
July 03, 2026 | News
METiS TechBio (7666.HK), a leading AI-driven drug delivery innovation company, announced it has entered into an exclusive global licensing agreement ...
July 02, 2026 | News
The collaboration leverages Colossal's marsupial de-extinction and conservation biotechnology platform to save the Tasmanian devil from a contagious cancer...
July 01, 2026 | News
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
July 01, 2026 | News
Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung ...
June 29, 2026 | News
Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical P...
June 25, 2026 | News
Most Read
Bio Jobs
News
Editor Picks